Abstract-Antipsychotic agents which are considered to depressive to the central nervous system (CNS) but free of dependence liability were used in combination with barbiturates or tranquilizers to study the physical dependence liability in the so-enhanced CNS depression. In the study of physical dependence formation, when CNS depression was maintained in an enhanced state during the continuous application of the drug combi nations, the withdrawal convulsions were enhanced in both frequency and severity. In the crossphysical dependence study, two-drug combinations, i.e., phenobarbital (PhB)-chloropromazine (CPZ), PhB-diphenhydramine (DPH) and nitrazepam-chlorprothixene, and 3-drug combinations, i.e., PhB CPZ-promethazine and PhB-CPZ-DPH were evaluated. The 2-drug combinations suppressed some of the withdrawal signs, but those at high dosages showed a tendency to aggravate the signs. The 3-drug combi nations differed from the 2-drug combinations in that the suppression of withdrawal signs was synergistically enhanced and the barbital withdrawal signs were weak. In conclusion, when CNS depression with PhB was enhanced with combinations of dependence liability-free drugs the drug combinations enhanced withdrawal convulsions both in frequency and severity. The sedation enhanced by the combinations did not always parallel the suppression of barbital withdrawal.
Compound preparations of hypnotics, antipsychotics and antihistaminics, i.e., so called -cocktail" preparations, have often been prescribed for drug therapy in internal medicine and psychiatry. Singh et al. (1) reported that diphenhydramine, an anti histaminic, enhanced physical dependence on methaqualone (2, 3) . From drug dependence liability, especially, physical dependence liability to sedative hypnotics, it is known that if the central nervous system (CNS) is continuously depressed day and night during the dosing period, the tolerance to and the grade of physical dependence on the drugs are enhanced (4) (5) (6) (7) . In the present study, drugs which are considered to be suppressive to the CNS but free of dependence liability were applied in combination with barbi turates or tranquilizers for the purpose of studying the tolerance and dependence liability and also to assess the mode of suppression of barbiturate withdrawal signs (cross-physical dependence liability test) in this soenhanced CNS depression.
Corre lations between their general CNS depressive actions and physical dependence liability or suppession of barbiturate withdrawal signs were also studied.
MATERIALS AND METHODS
Male Sprague-Dawley rats, 5 to 6 weeks old were used.
Tolerance study: The animals of the test group were given free access to a pheno barbital (PhB)-admixed food (1 mg/g food) containing chlorpromazine (CPZ, 0.63 mg/g food), i.e., PhB-CPZ combination, for 24 hr daily x15. The control animals were also given free access to a food containing only PhB, at the same concentration (1 mg/g food). The animals were checked regarding tolerance to PhB-induced motor incoordi nation by the rotarod performance test (6) , at given times every day.
Physical dependence liability study: The animals were used in the following 5 groups. PhB was, in principle, applied on a gradedly increasing dosage schedule, while the agents used in combination were applied at given levels throughout the dosing period. Each control animal at first was simultaneously given free access to a food containing PhB at 0.5 mg/g and food containing the drug at 1 mg/g (0.5 and 1 mg/g food) and was left in an individual cage for the first 10 days. The animal was then put on 1 and 2 mg/g food for the following 10 days; on 2 and 4 mg/ g food for the next 20 days, and on 3 mg/g food for the last 5 days, with 1 to 2-day withdrawal intervals during the 20-day period and also a 2-day withdrawal intervals during the 20-day period (G 5). Group 1 (G 1) was fed the same PhB-admixed food, as the control group, but additionally containing diphenhydramine (DPH) at the fixed concen tration of 0.5 mg/g food. Group 2 (G 2) was put on the same PhB-containing diet plus the addition of CPZ at 0.5 mg/g food. Group 3 (G 3) was given free access to 3-drug containing foods, i.e., the same PhB-admixed foods as for the controls but additionally containing DPH and CPZ, both at 1 /4 mg/g food.
Group 4 (G 4) was given a diet containing only CPZ at 0.5 mg/g food. Severities of withdrawal signs during the withdrawal intervals before each dosage period and during the 20-day dosing period were compared. The animals were weighed, and the food consumed measured daily during the experimental period. The rotarod performance test was performed daily on all groups, except G 2.
Cross-physical dependence liability study: Rats were made dependent on barbital by giving the drug to the animals on a gradedly increasing dosage schedule from the initial dosage of 0.5 and 1 mg/g food to the final dosage of 6 and 8 mg/g food over 36 days (6) . The drug combinations for cross application comprised PhB-DPH, PhB-CPZ, nitrazepam (NZP)-chlorprothixene (C PX), PhB-CPZ-promethazine (PMZ), and PhB CPZ-DPH. For the cross-application of these drugs, all medicated foods were replaced with a barbital-free, commercial diet at 17:00 hours of the scheduled day, and the drugs were, in principle, cross-applied p.o. several times, respectively, during the period from 17 hours of withdrawal (10:00 hours the following day) until 48 hours of withdrawal when severe withdrawal signs still persisted. Even at the start of the cross-application, moderate to severe withdrawal signs (6) were noted, that is, tremor, generalized muscular twitch sometimes with rigidity, motor incoordination of the 4 limbs and postural abnormalities, in all the rats, and clonic convulsions and weight losses in a few animals (Table 1) .
Considering the duration of CNS depression, or inhibitory effects on withdrawal signs, the cross application was performed at 4 to 6-hour intervals. The drugs were withdrawn for 5 to 6 days after the final cross-application was performed at 4 to 6-hour intervals. The drugs were withdrawn for 5 to 6 days after 
RESULTS
Tolerance study: Although the ingestion of PhB in the 2 groups was much the same (100 mg/kg/day on an average), the motor incoordination showed a reduction (acquire ment of tolerance) on the 4th day in the group on the food containing only PhB. Motor coordination was little changed by 5th day. In the group on the PhB-CPZ combination, motor coordination was always suppressed by 50% or more through 15 days of dosing. The suppression pattern of the drug used in combination indicated that CPZ in no way reduced or retarded the acquirement of tolerance to PhB (Fig. 1) .
Physical dependence liability: Figure 2 illustrates the dosage schedules of PhB only and in combination with other drugs and the daily drug intake. Regardless of the dosage, there were no significant differences in PhB intake among the 4 groups. However, a tendency toward a lesser intake was noted in the group given PhB only (G 5). The rotarod performance tests during the dosing period showed that suppression of motor coordination following ingestion of any of the drug combinations was obviously en hanced, compared with that by PhB only (Fig. 3) . CPZ alone caused a motor in corrdination and the related actions of the drugs used in combination were additive.
The weight loss rates on natural withdrawal after each of the dosage levels (I to IV) showed that none of the drug combinations enhanced barbital withdrawal signs through the first half of the III period (until 34 days of dosing), compared with PhB alone. The longer application of the drug combinations obviously enhanced and aggravated the withdrawal signs, compared with the ap plication of PhB. The withdrawal signs included tremor, hyperirritability, generalized muscular rigidity, ataxia, clonic and tonic convulsions.
The severest and longest lasting withdrawal signs were noted in the group dosed with the 3-drug combination. The motor incoordination induced by the triple drug combination was severe, even from the early stage of dosing, compared with effects induced by the 2-drug combi nations, and was correlated to the aggravation of PhB withdrawal signs by the prolonged application of the former. In all the dosed groups, the withdrawal signs were mani fested from about 24 hours of withdrawal onward, and were most severe at 48 to 72 hours: in other words, the drug combinations did not tend to either expedite or retard the peak manifestation of the signs (Fig. 3) . Cross-physical dependence study: At 24 hours of barbital withdrawal, withdrawal signs such as generalized muscular twitch, ataxia and turning over from the "kangaroo style" posture or stretching in a lateral position ("wave-like stretching") as postural abnormality-agony state occurred in all rats; and there were prodromal signs of clonic-tonic convulsions, in almost all animals. The cross-application of PhB at 10 and 30 mg/kg (the doses at a time) from this stage onward dose-relatedly suppressed the barbital withdrawal signs. The combination of PhB at the same doses and DPH also suppressed the withdrawal signs dose relatedly, but there was no tendency toward an enhanced supression of the withdrawal signs, compared with PhB alone (Fig. 4) . On resumption of barbital medication (at 2 and 4 mg/g food) 7 days after its withdrawal, there were rapid increases in food consumption and weight gain in all groups, thereby indicating that the barbital withdrawal signs were still present. Body weight was rapidly restored when the barbital-admixed food (2 and 4 mg/g food) was given after a 7-day withdrawal.
The cross-application of NZP, even at the low test dose of 3 mg/kg, from 17 hours of barbital withdrawal onward obviously sup pressed weight loss and anorexia. At 10 mg/kg, this cross-dosing suppressed almost all the severe withdrawal signs, while at the next dosing, Straub reaction and exaggerated pinna reflex were noted in all animals, and vocalization, muscular rigidity and clonic convulsions occurred in a few animals. The application of CPZ gave rise to the signs of CNS depression e.g., ptosis, decreased activity and staggering gait, and also catalepsy. This dosing, however, suppressed only slightly the barbital withdrawal signs, with severe withdrawal signs such as wild running, grand mal type convulsions and clonic-tonic con vulsions persisting.
This dosing was as sociated with decreases in food consumption and weight losses, as seen in the control group on withdrawal: CPZ proved to have no therapeutic effect in terms of behavioral signs (Fig. 5) . The NZP-CPX combination en hanced CNS depression; especially, the combination of NZP at a low dose and CPX enhanced the weak CNS depression with NZP only and was associated with a tendency toward suppression of irritability and muscular rigidity. This barbital withdrawal sign suppressive action of this combination, however, was not dose-related, with CPX at a high dose rather reducing the effect of NZP. From the general signs after the cross application, the CPX combination rather tended to enhance and prolong the duration of irritability, vocalization, aggressiveness, response to environmental stimuli and muscular rigidity, compared with the control group on withdrawal and the cross application of NZP. From the restoration of body weight, CPX at a high dose obviously rendered the prognosis poor.
The cross-application of PhB-NZP combi nation at further lower doses than the aforementioned ones (Fig. 4) suppressed withdrawal signs such as convulsions only weakly in the early stage, but from the 4th application onward, moderate CNS de pression persisted, with moderate withdrawal signs such as vocalization on touching, hyperirritability and muscular rigidity con tinuing.
In other words, the convulsion continued to be suppressed. On the other hand, neither relapse of marked withdrawal signs nor retardation in weight gain noted even after termination of the cross application, thereby demonstrating that the PhB-CPZ combination, at low doses was effective. the withdrawal signs all but completely, while termination was followed by relapse of only mild withdrawal signs. The PhB-PMZ combination was also effective in suppressing barbital withdrawal signs.
However, the withdrawal signs that relapsed after termination of the cross application of this combination tended to be severe and the recovery retarded, compared with findings after the dosing with the PhB DPH combination (Fig. 6 ). CPZ and sedative anti-histaminics, i.e., DPH, promethazine (PMZ). PhB+DPH combi nations significantly suppressed the withdrawal signs of barbital and, conversely, the intensity of recrudescences was attenuated.
DISCUSSION
In previous studies (6-12), Tagashira et al. established the dosage schedules for PhB and B dependence formation (Fig. 7) and the method for the evaluation of physical de pendence liability of sedative-hypnotic agents. The grade of CNS depression during dosing with such drugs was evaluated by rotarod performance test with the passage of time. The barbiturate withdrawal signs in rats, being close to those in humans (13), dogs (14) and monkeys (15) , serve as a model for the evaluation of results of preclinical studies of barbiturates. From the dose response relationship of the suppression of barbiturate withdrawal signs in the cross physical dependence study (10, 11) , varying withdrawal signs were classed into 3 levels: mild, moderate and severe (Table 1) .
CPZ (10, 11) If the cross application of drug has proved to essentially suppress barbital withdrawal signs, it appears to be a drug which improves 5-HT metabolism in the presynapses of the brain serotonergic neurons.
CPZ inhibits the accumulation of 5-HT and norepinephrine by monoamine oxidase inhibitors (18) . This action of CPZ is said to result from the inhibition of monoamine re-uptake due to stabilization of the synapse membrane (18) . From the state of elevation of 5-HT synthesis rate on barbital withdrawal, the inhibition of 5-HT uptake is identical to indirect antagonism to the metabolic turnover of 5-HT as are p chlorophenylalanine (5-HT synthesis in hibitor) and reserpine (depletion of mono amines), and in consequence it aggravates the barbital withdrawal signs. On the other hand, the drug combination of PhB-CPZ-DPH or PhB-CPZ-PMZ differed from the 2-drug combinations in mode of action; that is, the former synergistically enhanced the suppression of withdrawal signs, and the barbital withdrawal signs that relapsed were weak compared to the severity of the suppressive action. 
